Translate page

This Virtual Education Program, provided by the iCMLf offers a series of webcast presentations from leading hematologists.

These presentations provide updated information on treatment advances and best practice management of CML, including disease monitoring and new therapies. The sessions specifically address issues of CML care in countries with limited access to monitoring and supplemental treatments.

 

-- Virtual Education Program: 2019 Edition

 

Presentations from the COLT Meeting 2019

We are pleased to make available a series of presentations from the COLT Meeting 2019, a CML Opinion Leader Training that took place in Adelaide (Australia). Topics cover; CML therapy - state of science, management of CML, practicalities and monitoring TFR and Ph+ALL.


Timothy Hughes

David Yeung 3 Devendra Hiwase

Session 1: CML therapy - state of science
Chair: Prof. Tim Hughes

  • Frontline Therapy for CML 
    (Prof Tim Hughes)
  • When frontline therapy fails
    (Dr David Yeung)
  • CML - Beyond chronic phase
    (Dr Devendra Hiwase)

 

 

Naranie

David Yeung 3 Susan Branford                    

Session 2: CML Management, Practicalities
Chair: Dr David Yeung

  • Managing TKI toxicities
    (Dr Naranie Shanmuganathan)
  • Allograft - still a role in CML?
    (Dr David Yeung)
  • Molecular monitoring
    (A/Prof Susan Branford)

 

 

Susan Branford

 

David Yeung 3                  

 

Session 3: Monitoring TFR and Ph+ ALL
Chair: Dr Naranie Shanmunagathan

  • Monitoring TFR - Challenges 
    (A/Prof Susan Branford)
  • Ph+ ALL
    (Dr David Yeung)

 

 

David Ross Devendra Hiwase Michael Osborn                    

Session 4: CML related topics
Chair: Dr David Ross

  • Myelofibrosis Management
    (Dr David Ross)
  • MPN/MDS Overlap Syndrome
    (Dr David Ross)
  • Pediatric CML
    (Dr Michael Osborn)

 

 

IMG 9703 John Reynolds

David Ross Timothy Hughes                    

Session 5: The CML frontier
Chair: Prof Timothy Hughes

  • Biostats primer for CML clinicians
    (A/Prof John Reynolds)
  • TFR trial update
    (Dr David Ross)
  • Making TFR mainstream
    (Prof Timothy Hughes)